View in EDS

Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).

Saved in:
Bibliographic Details
Title: Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).
Authors: Dummer, R.1, Duvic, M.2, Scarisbrick, J.3, Olsen, E. A.4, Rozati, S.1, Eggmann, N.1, Goldinger, S. M.1, Hutchinson, K.5, Geskin, L.6, Illidge, T. M.7, Giuliano, E.8, Elder, J.9, Kim, Y. H.10
Source: Annals of Oncology. Sep2014, Vol. 25 Issue 9, p1807-1812. 6p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdu231